LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

Search

Novartis AG

Gesloten

109.54 1.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

109.18

Max

109.58

Belangrijke statistieken

By Trading Economics

Inkomsten

786M

3.6B

Verkoop

62M

14B

K/W

Sectorgemiddelde

17.077

56.602

EPS

2.28

Dividendrendement

3.67

Winstmarge

26.476

Werknemers

75,883

EBITDA

643M

5.8B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-2.36% downside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.67%

2.45%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-765M

217B

Vorige openingsprijs

108.45

Vorige sluitingsprijs

109.54

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Novartis AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2025, 09:36 UTC

Belangrijke Marktbewegers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 apr 2025, 16:35 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 apr 2025, 11:55 UTC

Acquisities, Fusies, Overnames

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 apr 2025, 11:54 UTC

Acquisities, Fusies, Overnames

Novartis to Acquire Regulus in $1.7 Billion Deal

29 apr 2025, 07:09 UTC

Winsten

Novartis Lifts Guidance After Profit, Sales Top Views -- Update

29 apr 2025, 05:36 UTC

Winsten

Novartis Lifts Guidance After Profit, Sales Top Views

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mei 2025, 18:45 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

30 apr 2025, 11:40 UTC

Acquisities, Fusies, Overnames

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 apr 2025, 11:39 UTC

Acquisities, Fusies, Overnames

Novartis to Acquire Regulus in $1.7B Deal

30 apr 2025, 11:16 UTC

Acquisities, Fusies, Overnames

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 apr 2025, 11:15 UTC

Acquisities, Fusies, Overnames

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 apr 2025, 11:14 UTC

Acquisities, Fusies, Overnames

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 apr 2025, 11:13 UTC

Acquisities, Fusies, Overnames

Novartis to Buy Regulus Therapeutics

29 apr 2025, 12:34 UTC

Marktinformatie
Winsten

Novartis Solid Result Shifts Investor Focus to 2H -- Market Talk

29 apr 2025, 11:54 UTC

Marktinformatie
Winsten

Correction to Novartis Market Talk

29 apr 2025, 11:47 UTC

Marktinformatie
Winsten

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

29 apr 2025, 10:42 UTC

Marktinformatie
Winsten

Novartis Surprises With Another Beat & Raise -- Market Talk

29 apr 2025, 10:16 UTC

Marktinformatie
Winsten

Novartis's Guidance Lift Reflects Strong Sales -- Market Talk

29 apr 2025, 05:06 UTC

Winsten

Novartis Had Seen Core Operating Profit to Grow at High Single to Low Double-Digit in 2025 at Constant Currencies

29 apr 2025, 05:06 UTC

Winsten

Novartis Expects Core Operating Profit to Grow Low Double-Digit in 2025 at Constant Currencies

29 apr 2025, 05:05 UTC

Winsten

Novartis Had Seen Sales Grow Mid- to High-Single Digit in 2025 at Constant Currencies

29 apr 2025, 05:04 UTC

Winsten

Novartis Expects Sales to Grow High Single Digit in 2025 at Constant Currencies

29 apr 2025, 05:02 UTC

Winsten

Novartis Raises 2025 View

29 apr 2025, 05:02 UTC

Winsten

Analysts Had Seen Novartis 1Q Rev $13.00B

29 apr 2025, 05:02 UTC

Winsten

Novartis 1Q Rev $13.23B

29 apr 2025, 05:01 UTC

Winsten

Analysts Had Seen Novartis 1Q Core Operating Profit EUR5.22B

29 apr 2025, 05:01 UTC

Winsten

Novartis 1Q Core Operating Profit EUR5.575B

29 apr 2025, 05:00 UTC

Winsten

Novartis AG 1Q Adj EPS $2.28

29 apr 2025, 05:00 UTC

Winsten

Novartis AG 1Q EPS $1.83

Peer Vergelijking

Prijswijziging

Novartis AG Prognose

Koersdoel

By TipRanks

-2.36% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 107 USD  -2.36%

Hoogste 116 USD

Laagste 88 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novartis AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

2

Buy

2

Hold

1

Sell

Technische score

By Trading Central

N/A / 112.63Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.